A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

<p>Abstract</p> <p>Background</p> <p>The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer.</p>...

Full description

Bibliographic Details
Main Authors: Trejo-Becerril Catalina, Sandoval Karina, Cabrera Gustavo, Angeles Enrique, Chavez-Blanco Alma, Taja-Chayeb Lucía, Revilla-Vazquez Alma, Cetina Lucely, Perez-Cardenas Enrique, Segura-Pacheco Blanca, Zambrano Pilar, Chanona-Vilchis Jose, Duenas-González Alfonso
Format: Article
Language:English
Published: BMC 2005-04-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/5/44

Similar Items

Similar Items